Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
November 14, 2022 at 02:48 am EST
Share
Abbott India Limited reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported sales was INR 13,794.8 million compared to INR 12,220.6 million a year ago. Revenue was INR 14,130.1 million compared to INR 12,402.7 million a year ago. Net income was INR 2,655.2 million compared to INR 1,923.3 million a year ago. Basic earnings per share from continuing operations was INR 124.95 compared to INR 90.51 a year ago.
For the six months, sales was INR 26,838.5 million compared to INR 24,398.9 million a year ago. Revenue was INR 27,437.4 million compared to INR 24,773.1 million a year ago. Net income was INR 4,711.6 million compared to INR 3,880.9 million a year ago. Basic earnings per share from continuing operations was INR 221.72 compared to INR 182.63 a year ago.
Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.
ABBOTT INDIA LIMITED 
